Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study

Circulation

Volumn 101, Issue 24, 2000, Pages 2777-2782

  Austin, Melissa A ^a   McKnight, Barbara ^b   Edwards, Karen L ^a   Bradley, Cynthia M ^a   McNeely, Marguerite J ^c   Psaty, Bruce M ^c   Brunzell, John D ^a   Motulsky, Arno G ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular diseases; Follow up studies; Hyperlipoproteinemia; Lipids; Mortality

Indexed keywords

TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FAMILIAL HYPERLIPEMIA; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RELATIVE; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0034691299     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.24.2777     Document Type: Article

References (47)

1. Brunzell JD, Schrott HG, Motulsky AG, et al. Myocardial infarction in the familial forms of hypertriglyceridemia. Metabolism. 1976;25: 313-320.
2. Goldstein JL, Schrott HG, Hazzard WR, et al. Hyperlipidemia in coronary heart disease, II: genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 1973;52:1544-1568.
3. Genest JJ Jr, Martin-Munley SS, McNamara JR, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation. 1992;85:2025-2033.
4. Schaefer EJ, Genest JJJ, Ordovas JM, et al. Familial lipoprotein disorders and premature coronary artery disease. Atherosclerosis. 1994;108: S41-S54.
5. Goldstein JL, Hazzard WR, Schrott HG, et al. Hyperlipidemia in coronary heart disease, I: lipid levels in 500 survivors of myocardial infarction. J Clin Invest. 1973;52:1533-1543.
6. Hazzard WR, Goldstein JL, Schrott MG, et al. Hyperlipidemia in coronary heart disease. III: evaluation of lipoprotein phenotypes of 156 genetically defined survivors of myocardial infarction. J Clin Invest. 1973;52: 1569-1577.
7. Nikkila EA, Aro A. Family study of serum lipids and lipoproteins in coronary heart-disease. Lancet. 1973;1:954-959.
8. Scandinavian Simvastalin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344: 1383-1389.
9. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Meet. 1995;333:1301-1307.
10. Austin MA. Triglycerides and coronary heart disease. Arterioscler Thromb. 1991;11:2-14.
11. NIH Consensus Development Panel on Triglyceride High-Density Lipoprotein, and Coronary Heart Disease. Triglyceride, high-density lipoprotein, and coronary heart disease. JAMA. 1993;269:505-510.
12. Gotto AM. Triglyceride: the forgotten risk factor. Circulation. 1998;97: 1027-1028.
13. Hokanson JE, Austin MA. Triglyceride is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol: a meta-analysis of population-based prospective studies. J Cardiol Risk. 1996;3: 213-219.
14. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol. 1996;77:1179-1184.
15. Jeppsen J, Hein HO, Suadicani P, et al. Triglyceride concentration and ischemic heart disease: an 8-year follow-up in the Copenhagen Male Study. Circulation. 1998;97:1029-1036.
16. Bierman EL, Hamlin JTI. The hyperlipidemic effect of a low-fat, high carbohydrate diet in diabetic subjects. Diabetes. 1961;10:432-436.
17. Carlson L. Determination of serum glycerides. Acta Soc Med Ups. 1959; 64:208-213.
18. Bachorik PS, Albers JJ. Precipitation methods for quantification of lipoproteins. In: Albers JJ, Segrest JP, eds. Methods in Enzymology. New York, NY: Academic Press; 1986:78-100.
19. Ives DG, Fitzpatrick AL, Bild DE, et al. Surveillance and ascertainment of cardiovascular events: the Cardiovascular Health Study. Ann Epidemiol. 1995;5:278-285.
20. National Death Index User's Manual. Centers for Disease Control and Prevention/National Center for Health Statistics: Hyattsville, Md: US Department of Health and Human Services; 1997.
21. Cox DR. Regression models and life tables (with discussion). J R Stat Soc [Series B. Methodological]. 1972;34:187-220.
22. Breslow NE, Day NE. The Design and Analysis of Cohort Studies. Lyon, France: International Agency for Research on Cancer; 1987.
23. Lee EW, Wei LJ, Amato DA. Cox-type regression analysis for large numbers of small groups of correlated failure time observations. In: Klein JP, Goel PK, eds. Survival Analysis: State of the Art. Dordrecht, Netherlands: Kluwer Academic Publishers; 1992:237-247.
24. Brunzell JD, Hazzard WR, Motulsky AG, et al. Evidence for diabetes mellitus and genetic forms of hypertriglyceridemia as independent entities. Metabolism. 1975;24:1115-1121.
25. Williams EN. A Sensitivity Analysis for the Genetic Epidemiology of Hypertriglyceridemia Study. Seattle, Wash: University of Washington; 1998.
26. Tenkate LP, Bowman H, Daiger SP, et al. Increased frequency of coronary heart disease in relatives of wives of myocardial infarct survivors: assortative mating for lifestyle and risk factor? Am J Cardiol. 1984;53: 399-403.
27. Chait A, Albers JJ, Brunzell JD. Very low density lipoprotein overproduction in genetic forms of hypertriglyceridaemia. Eur J Clin Invest. 1980;10:17-22.
28. Kissebah AH, Alfarsi S, Evans DJ. Low density lipoprotein metabolism in familial combined hyperlipidemia: mechanism of the multiple lipoprotein phenotypic expression. Arteriosclerosis. 1984;4:614-624.
29. Janus ED, Nicoll AM, Turner PR, et al. Kinetic bases of the primary hyperlipidaemias: studies of apolipoprotein B turnover in genetically defined subjects. Eur J Clin Invest. 1980;10:161-172.
30. Austin MA, Brunzell JD, Fitch WL, et al. Inheritance of low density lipoprotein subclass patterns in familial combined hyperlipidemia. Arteriosclerosis. 1990;10:520-530.
31. Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996;276:882-888.
32. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 1996;276:875-881.
33. Austin MA, Breslow JL, Hennekens CH, et al. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260: 1917-1921.
34. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Circulation. 1997;95:69-75.
35. Sniderman A, Shapiro S, Marpole D, et al. Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density (beta) lipoproteins]. Proc Natl Acad Sci USA. 1980;77:604-608.
36. Angelin B, Hershon KS, Brunzell JD. Bile acid melabolism in hereditary forms of hypertriglyceridemia: evidence for an increased synthesis rate in monogenic familial hypertriglyceridemia. Proc Natl Acad Sci USA. 1987;84:5434-5438.
37. Duane WC. Abnormal bile acid absorption in familial hypertriglyceridemia. J Lipid Res. 1995;36:96-107.
38. Pajukanta P, Nuotio I, Terwilliger JD, et al. Linkage of familial combined hyperlipidaemia to chromosome 1q21-q23. Nat Genet. 1998;18: 369-373.
39. Aouizerat BE, Allayee H, Cantor RM, et al. A genome scan for familial combined hyperlipidemia reveals evidence of linkage with a locus on chromosome 11. Am J Hum Genet. 1999;65:397-412.
40. Cabezas MC, de Bruin TW, de Valk HW, et al. Impaired fatty acid metabolism in familial combined hyperlipidemia: a mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J Clin Invest. 1993;92:160-168.
41. de Bruin TW, Mailly F, van Barlingen HH, et al. Lipoprotein lipase gene mutations D9N and N291S in 4 pedigrees with familial combined hyperlipidaemia. Eur J Clin Invest. 1996;26:631-639.
42. Yang WS, Nevin DN, Iwasaki L, et al. Regulatory mutations in the human lipoprotein lipase gene in patients with familial combined hyperlipidemia and coronary artery disease. J Lipid Res. 1996;37:2627-2637.
43. Reynisdottir S, Angelin B, Langin D, et al. Adipose tissue lipoprotein lipase and hormone-sensitive lipase: contrasting findings in familial combined hyperlipidemia and insulin resistance syndrome. Arteriosder Thromb Vasc Biol. 1997;17:2287-2292.
44. Criqui MH, Heiss G, Cohn R, et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med. 1993;328:1220-1225.
45. Haim M, Benderly M, Brunner D, et al, for the BIP Study Group. Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Benzafibrate Infarction Prevention (BIP) Registry. Circulation. 1999;100:475-482.
46. Ooi TC, Heinonen T, Alaupovic P, et al. Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, Atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate. Arteriosder Thromb Vasc Biol. 1997;17:1793-1799.
47. Ellen RLB, McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol. 1998;81(4A):60B-65B.